{"version":"1.0","type":"link","title":"5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC.","author_name":"Liu SV 외","author_url":"https://prs-insight.online/author/Liu%20SV","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/171574","thumbnail_width":1200,"thumbnail_height":630}